China Tracker - Details for China Kanghui Holdings (KH)

 China Kanghui Holdings
 Business Outlook

Reflecting on our strong second quarter performance and continued demand for all of our product lines, both domestically and internationally, we are increasing our revenue and net income guidance for full year 2011.

The Company anticipates revenue for full year 2011 will increase to the range of RMB303 million to RMB313 million, which represents year-over-year growth of 25% to 29%. This compares to the Company's previous 2011 revenue guidance of RMB292 million to RMB303 million. The Company estimates non-GAAP net income for full year 2011 will increase to the range of RMB122 million to RMB127 million, compared to its previous estimate of RMB121 million to RMB126 million.

(Source: PR Newswire, 2011-08-15)

The Company expects year-over-year revenue growth of 20% to 25% in 2011, bringing revenue for the full year 2011 in the range of RMB292 million to RMB303 million. The Company also expects its full year 2011 non-GAAP net income, without taking into account relevant operating expenses in connection with the exclusive partnership with Consensus Orthopedic and the acquisition of the majority stake in Wei Rui Li, to be in the range of RMB128 million to RMB133 million. The impact of the exclusive partnership with Consensus Orthopedic and the acquisition of the majority stake in Wei Rui Li on the Company's operating expenses is expected to be approximately RMB7 million. After taking into account the operating expenses relating to these transactions, the Company believes that non-GAAP net income for the full year 2011 will be between RMB121 million and RMB126 million.

(Source: Business Wire, 2011-05-16)

China Kanghui Holdings today announced that it has acquired a majority stake in Beijing Wei Rui Li Medical Device Co., a provider of approved hip and knee systems in China. The Company expects to acquire 60% of Wei Rui Li. Pursuant to the share purchase agreement, the Company has the option to acquire additional equity interest in Wei Rui Li at a pre-determined price subject to the achievement of certain milestones. The transaction is expected to close by March 31, 2011, subject to all conditions set out in the share purchase agreement being satisfied.

(Source: Business Wire, 2011-03-23)

The Company expects year-over-year revenue growth of 20% to 25% in 2011, bringing revenue for the full year 2011 in the range of RMB292 million to RMB303 million. The Company also expects its full year 2011 non-GAAP net income to be in the range of RMB128 million to RMB133 million, excluding the impact of operating expenses related to the exclusive partnership with Consensus Orthopedics and the acquisition of the majority stake in Wei Rui Li. After taking into account the operating expenses relating to these transactions, the Company believes that non-GAAP net income for the full year 2011 will be between RMB121 million and RMB126 million.

(Source: Business Wire, 2011-03-23)

Our third quarter financial results reflect continued fundamental strength in our business. With our successful initial public offering earlier this year, we have obtained considerable resources to implement our growth plans going forward, in the fast-growing Chinese market. According to Frost & Sullivan, the market for orthopedic products in China was approximately RMB6.1 billion in 2009 and is expected to reach RMB16.6 billion by 2015. We are working to ensure we effectively capitalize on this opportunity in China, as well as stay focused on our goals to drive international growth and offer innovative and diversified orthopedic product lines. ... Over the next year, we will continue to execute our growth strategy by expanding internationally and capitalizing on consolidation opportunities in the Chinese market.

(Source: Business Wire, 2010-11-08)
KH
Healthcare & Drugs
SCORE
2
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH SAFETY
DETAILS: Safety/Risk Model for KH
Current Price:  n/a
F10k Day (2010-08-11): -100.00%$12.16
2010 Close: -100.00%$18.51
2011 Close: -100.00%$14.74
High (2012-10-15): -100.00%$30.74
Low (2012-05-25): -100.00%$18.72
Exchange: N/A
Market Capitalization: n/a
Total Shares: 25.14 mill
Float: n/a
Avg Volume: 261.20 k
Short Interest: 1.33 mill
Short Ratio: 0.30%5.1 d
Last Quarter: 2011-03-31
Revenue (MRQ): 10.38 mill
Net Income (MRQ): 3.55 mill
all financial data provided without warranty